A systematic review of off-label uses of memantine for psychiatric disorders

Zdanys, Kristina; Tampi, Rajesh R.

doi:10.1016/j.pnpbp.2008.01.008

Cited by 91 publications

(48 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present findings do not address the potential therapeutic value of memantine in daily dosing regimens in CPD (the evidence of which is mixed: de Lucena et al, 2009;Lieberman et al, 2009;Krivoy et al, 2007;Zdanys & Tampi, 2008), but do suggest the value for some CPD patients of adding an acute pharmacologic challenge with memantine to augment cognitive therapies that would benefit from gains in pre-attentive information processing (Swerdlow, 2011a,b,). Of course, memantine may not be the optimal drug for such a strategy: newer analogs of this compound have been developed, and our ongoing studies are assessing other drug classes Swerdlow et al, 2014).…”

Section: Discussionmentioning

confidence: 55%

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Swerdlow

Bhakta

Chou

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

Patients with chronic psychotic disorders (CPD) exhibit deficient sensorimotor gating (measured by prepulse inhibition (PPI) of startle) and mismatch negativity (MMN). In healthy subjects (HS), N-methyl-D-aspartate (NMDA) antagonists like memantine and ketamine increase PPI, and under some conditions, memantine enhances MMN; these findings present a challenge to understanding the basis for deficient PPI and MMN in psychotic disorders, as reduced NMDA activity is implicated in the pathogenesis of these disorders. Here we assessed for the first time the effects of memantine on PPI and MMN in CPD subjects. Baseline PPI was measured in HS and patients with a diagnosis of schizophrenia or schizoaffective disorder, depressed type. Subjects (total n = 84) were then tested twice, in a double-blind crossover design, comparing either: (1) placebo vs 10 mg of memantine or (2) placebo vs 20 mg memantine. Tests included measures of acoustic startle magnitude and habituation, PPI, MMN, autonomic indices, and subjective self-rating scales. Memantine (20 mg) significantly enhanced PPI in CPD subjects, and enhanced MMN across subject groups. These effects on PPI were age dependent and most evident in older CPD patients, whereas those on MMN were most evident in younger subjects. The lower dose (10 mg) either had no detectable effect or tended to degrade these measures. The NMDA antagonist, memantine, has dose-dependent effects on preconscious, automatic measures of sensorimotor gating and auditory sensory processing that are associated with enhanced cognition and function in CPD patients. Ongoing studies will determine whether these memantine-induced changes predict acute pro-cognitive or otherwise clinically beneficial effects in CPD patients.

show abstract

Section: Discussionmentioning

confidence: 55%

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Swerdlow

Bhakta

Chou

et al. 2015

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Efficacy has now been shown in randomized controlled trials in a variety of dementias [288]. Memantine might also have beneficial effects in other disorders, including Parkinson disease, stroke, epilepsy, trauma, drug dependence and chronic pain [289][290][291][292][293], but additional research is needed.…”

Section: Introductionmentioning

confidence: 99%

The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development

Blasco¹,

Mavel²,

Corcia³

et al. 2014

CMC

139

View full text Add to dashboard Cite

“…On the other hand, new studies have attributed other individual properties to memantine in some disorders, including schizophrenia, bipolar disorder and depression (reviewed in Zdanys and Tampi 2008). Preclinical studies have demonstrated that memantine displays antidepressant-like effects in rats subjected to animal models of depression (Réus et al 2010;Almeida et al 2006;Skuza and Rogóz 2003;Rogóz et al 2002).…”

Section: Introductionmentioning

confidence: 99%

Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain

et al. 2011

View full text Add to dashboard Cite

Several studies have appointed for a role of glutamatergic system and/or mitochondrial function in major depression. In the present study, we evaluated the creatine kinase and mitochondrial respiratory chain activities after acute and chronic treatments with memantine (N-methyl-D: -aspartate receptor antagonist) and imipramine (tricyclic antidepressant) in rats. To this aim, rats were acutely or chronically treated for 14 days once a day with saline, memantine (5, 10 and 20 mg/kg) and imipramine (10, 20 and 30 mg/kg). After acute or chronic treatments, we evaluated mitochondrial respiratory chain complexes (I, II, II-III and IV) and creatine kinase activities in prefrontal cortex, hippocampus and striatum. Our results showed that both acute and chronic treatments with memantine or imipramine altered respiratory chain complexes and creatine kinase activities in rat brain; however, these alterations were different with relation to protocols (acute or chronic), complex, dose and brain area. Finally, these findings further support the hypothesis that the effects of imipramine and memantine could be involve mitochondrial function modulation.

show abstract

A systematic review of off-label uses of memantine for psychiatric disorders

Cited by 91 publications

References 92 publications

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis

The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development

Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain

Contact Info

Product

Resources

About